Deucravacitinib (Sotyktu™) for plaque psoriasis

Trends Pharmacol Sci. 2023 Apr;44(4):252-253. doi: 10.1016/j.tips.2023.01.004. Epub 2023 Feb 23.

Authors

Agnete Marie Granau¹, Theresa Louise Boye¹, Kim Bak Jensen², Ole Haagen Nielsen³

Affiliations

¹ Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.
² Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
³ Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. Electronic address: ole.haagen.nielsen@regionh.dk.

PMID: 36841716
DOI: 10.1016/j.tips.2023.01.004

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal
Humans
Psoriasis* / drug therapy
Treatment Outcome

Substances

deucravacitinib
Antibodies, Monoclonal